Login
- Title:
Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial.
- Document type:
- Journal Article; Article
- Author(s):
- Lorenzen, S; Brucher, B; Zimmermann, F; Geinitz, H; Riera, J; Schuster, T; Roethling, N; Höfler, H; Ott, K; Peschel, C; Siewert, JR; Molls, M; Lordick, F
- Abstract:
- Oxaliplatin and 5-fluorouracil have a significant activity in locally advanced oesophageal squamous cell cancer (OSCC). However, their optimal dosage and efficacy when combined with concurrent radiotherapy as neoadjuvant treatment are unknown. This non-randomised, phase I/II study aimed to define the maximum tolerated dose (MTD) and assessed the histopathological tumour response rate to neoadjuvant oxaliplatin in weekly escalating doses (40, 45, 50 mg m(-2)) and continuous infusional 5-fluorouracil (CI-5FU; 225 mg m(-2)) plus concurrent radiotherapy. Patients had resectable OSCC. Resection was scheduled for 4-6 weeks after chemoradiotherapy. During phase I (dose escalation; n=19), weekly oxaliplatin 45 mg m(-2) plus CI-5FU 225 mg m(-2) was established as the MTD and was the recommended dosage for phase II. Oesophageal mucositis was the dose-limiting toxicity at higher doses. During phase II, histopathological responses (<10% residual tumour cells within the specimen) were observed in 10 of 16 patients (63%; 95% confidence interval: 39-82%). Overall, 16 of the 25 patients (64%) who underwent resection had a histopathological response; tumour-free resection (R0) was achieved in 80%. Neoadjuvant weekly oxaliplatin 45 mg m(-2) plus CI-5FU 225 mg m(-2) with concurrent radiotherapy provides promising histological response rates and R0 resection rates in locally advanced OSCC.
- Journal title abbreviation:
- Br J Cancer
- Year:
- 2008
- Journal volume:
- 99
- Journal issue:
- 7
- Pages contribution:
- 1020-6
- Language:
- eng
- Fulltext / DOI:
- doi:10.1038/sj.bjc.6604659
- Pubmed ID:
- http://view.ncbi.nlm.nih.gov/pubmed/18797462
- Print-ISSN:
- 0007-0920
- TUM Institution:
- III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Allgemeine Pathologie und Pathologische Anatomie; Institut für Medizinische Statistik und Epidemiologie; Klinik und Poliklinik für RadioOnkologie und Strahlentherapie
BibTeX
Occurrences:
- mediaTUM GesamtbestandEinrichtungenSchools TUM School of Medicine and HealthDepartmentsClinical MedicineInstitut für KI und Informatik in der Medizin (Prof. Rückert)2008
- mediaTUM GesamtbestandHochschulbibliographie2008FakultätenMedizinInstitut für Medizinische Statistik und Epidemiologie
- mediaTUM GesamtbestandEinrichtungenSchools TUM School of Medicine and HealthDepartmentsClinical MedicineKlinik und Poliklinik für RadioOnkologie und Strahlentherapie (Prof. Combs)2008
- mediaTUM GesamtbestandEinrichtungenSchools TUM School of Medicine and HealthDepartmentsPreclinical MedicineInstitut für Allgemeine Pathologie und Pathologische Anatomie (Dr. Mogler komm.)2008
- mediaTUM GesamtbestandEinrichtungenSchools TUM School of Medicine and HealthDepartmentsClinical MedicineKlinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann)2008